JUN and sarcoma: In a large case-control study of six different sarcoma subtypes, three prognostic clusters were identified through integration of somatic CNAs and DNA methylation data in dedifferentiated liposarcoma, in which the first two groups (JUN amplified and TERT amplified with chromosome instability) had a worse survival rate than the third cluster (6q25.1 amplified and less unbalanced chromosome segments), with JUN identified as a potential therapeutic target due to its overexpression previously being shown to increase tumour migration and invasion [49].